Therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea.
Treatment of the myeloid blast phase of chronic granulocytic leukemia is still a major problem in clinical hematology. Alternate-day plicamycin and hydroxyurea treatment was reported to induce remissions in the majority of patients with myeloid blast phase by Koller and Miller in 1986 Subsequently we treated eight patients according to this regimen. Complete remissions could not be achieved and no prolongation of median survival was observed. In two patients treatment had to be discontinued due to severe toxicity.
Trümper
L H
LH
Medizinische Klinik, Heidelberg, Federal Republic of Germany.
Ho
A D
AD
Hunstein
W
W
van der Lelie
H
H
Goudsmit
R
R
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001752:Blast Crisis / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D008926:Plicamycin / Q000627:therapeutic use; D012189:Retrospective Studies
D008926:Plicamycin; D006918:Hydroxyurea